PHA's Research Program
"PHA's research program funds some of the best science and the brightest people in the nation."
- Dr. John Newman, Vanderbilt University Medical Center
PHA's Research Program has committed more than $15 million to support cutting-edge research focused on pulmonary hypertension. PHA has been able to leverage such substantial funding through partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the Foundation of the American Thoracic Society (ATS).
PHA's grants to promising researchers cultivate new leaders in the field by supporting their interest in PH research and providing them with opportunities to work with mentors and learn new skills. Researchers supported by PHA are looking for new methods for early detection, new treatments to prevent the onset of PH and ultimately a cure for this terrible illness.
Offering five active, independently reviewed cutting-edge research programs each year, PHA has awarded grants to more than 70 researchers since the inception of the program.
Robyn Barst Pediatric PH Research and Mentoring Program
A unique grant opportunity designed to fund mentoring and research opportunities in pediatric PH.
Learn more | Previous winners
PHA Proof of Concept Research Grants
This program offers support for new research projects that should result in the development of data enabling the investigator to apply for a larger, hypotheses-driven research project.
PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension
A partnership grant program with the Foundation of the American Thoracic Society supporting faculty-level researchers.
PHA/NHLBI Mentored Clinical Scientist Award (K08)/Mentored Patient-Oriented Research Career Development Award (K23)
A partnership with the National Heart, Lung, and Blood Institute (NHLBI) that supports junior investigators.
A partnership with the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health that supports a comprehensive, deep-phenotyping across the current World Health Organization (WHO) classifications of pulmonary hypertension (Groups 1 through 5).